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Familial porphyria cutanea tarda (PCT) is a photocutaneous disease in which subnormal activity of uropor- 
phyrinogen decarboxylase is observed both in the liver and red cells. Hepatic iron plays a key role in the 
genesis of overt biochemical and clinical PCT. In this report, we have studied the properties of lOOOO-fold 
purified erythrocyte uroporphyrinogen decarboxylase preparations from two familial PCT patients and a 
non-porphyric control subject. The apparent Michaelis constants (K,,,), determined by using uroporphyrino- 
gen III substrate, were approx. 3.2-times higher for the enzyme from the diseased subjects (K, = N 1.0 PM) 
as compared to the normal (K, = 0.3 PM). Though both abnormal and normal enzymes were inhibited pro- 
gressively with increasing concentrations of iron, the enzymes from diseased subjects exhibited greater sus- 
ceptibility e.g. 0.1 mM Fez+ inhibited the former about 50% and the latter about 20%. These observations 
suggest hat (i) the inherent biochemical defect in PCT is the reduced enzyme-substrate affinity and (ii) the 
intrinsic abnormal conformation renders the PCT enzyme particularly susceptible to inhibition by iron. 
Porphyria cutanea tarda Uroporphyrinogen akcarboxylare Human disease Erythrocyte Porphyrin 
Intracellular iron 
1. INTRODUCTION 
Interest in uroporphyrinogen decarboxylase (EC 
4.1.1.37), an enzyme which is involved in mam- 
malian heme biosynthesis, has been heightened by 
recent data that suggest the genesis of human por- 
phyria cutanea tarda (PCT) might be associated 
with an intrinsic abnormality of the enzyme [l] in 
combination with its interaction with microen- 
vironmental factors in the hepatocyte such as iron 
121. The disease is expressed as a photocutaneous 
skin lesion due to the accumulation of porphyrins 
in the skin. 
Recent observations of an approximate 50% 
reduction in uroporphyrinogen decarboxylase ac- 
tivity both in the liver and erythrocytes of familial 
PCT patients 13-51 and immunochemical studies 
[6], all suggest hat the red cell and liver enzymes 
are encoded by the same gene. However, reduced 
enzyme activity per se should not lead to 
biochemically active disease because: (i) in- 
trahepatic substrate concentrations normally are 
well below the Michaelis constant (Km) of uropor- 
phyrinogen decarboxylase, whose activity is 
50-lOO-fold in excess of rate-limiting heme biosyn- 
thetic enzymes [7], and (ii) the clinical and 
biochemical expression of the enzyme defect in 
PCT is rarely spontaneous and almost invariably is 
associated with hepatic iron overload [8] usually 
with alcoholic liver disease. Reduction of storage 
iron by phlebotomy predictably effects clinical and 
biochemical remission [9,10] which is reversed by 
oral iron ingestion [l 11. 
In this report, we have for the first time con- 
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ducted comparative kinetic studies of highly 
purified (about lOOOO-fold) erythrocyte enzyme 
preparations procured from 2 familial PCT pa- 
tients and a non-porphyric control subject. The 
purpose was to address the twin questions (a) the 
nature of inherent uroporphyrinogen decarbox- 
ylase enzyme defect in PCT and (b) the suscep- 
tibility of defective enzyme to iron. 
2. EXPERIMENTAL 
Erythrocytes were collected from 2 unrelated pa- 
tients with familial PCT and one non-PCT control 
subject: patient GB, has congenital porphyria 
thought to reflect bone marrow expression of 
familial PCT [12]. Patient AB, has classical overt 
familial PCT with liver disease diagnosed by 
criteria as described elsewhere [l]. The non- 
porphyric control subject FJMc has hemo- 
chromatosis with increased liver iron, normal 
hemolysate uroporphyrinogen decarboxylase ac- 
tivity and no biochemical evidence of PCT. 
Sources of chemicals have been described [1,2]. 
The enzymes were purified approx. lOOOO-fold 
with a specific activity of about 110 units/mg pro- 
tein using pentacarboxylic porphyrinogen I as 
substrate. Purification procedures, the details of 
which will be published elsewhere (Mukerji et al., 
in preparation) included DEAE-cellulose chro- 
matography, ammonium sulfate fractionation 
(40-70% saturation), Sephadex G-100 chro- 
matography and affinity chromatography on 
uroporphyrin-Sepharose. The enzyme was assayed 
and the Michaelis constant (K,,,) determined, using 
uroporphyrinogen III substrate, by HPLC 
analyses as described by Mukerji et al. [1,2]. 
3. RESULTS 
The data reported in fig.1 and table 1 show that 
the apparent Michaelis constants (K,,,) calculated 
from the Lineweaver-Burk double reciprocal plots, 
using uroporphyrinogen III as substrate, of the 
highly purified uroporphyrinogen decarboxylase 
from the erythrocytes of familial PCT patients 
(GB and AB) were about 3.2-times higher as com- 
pared to the K,,, values determined for similarly 
purified red cell enzyme from the hemo- 
chromatosis patient (FJMc). The Km values of the 
enzymes were 1 .OO and 0.96 PM for the PCT pa- 
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Fig.1. Lineweaver-Burk double reciprocal plots of rate 
versus average uroporphyrinogen III substrate 
concentration (0.05-6.0 FM) for lOOOO-fold purified red 
cell uroporphyrinogen decarboxylase from a normal 
control (FMc) (0) and 2 patients GB (0) and AB (A) 
with familial PCT. The lines passing through the 
experimental points were drawn after calculation using 
linear regression analysis. 
Table 1 
Michaelis constants (Km) of uroporphyrinogen 
decarboxylase highly purified (lOOOO-fold) from the 
erythrocytes of non-porphyric control and patients with 
familial porphyria cutanea tarda 
Human subject? nb K,,,' ?d 
GM) 
Non-porphyric control (FJMc) 2 0.31 0.99 
Familial PCT (GB) 2 1.00 0.99 
Familial PCT (AB) 2 0.96 0.99 
a Patients, FJMc was a hemochromatosis patient who 
had normal red cell uroporphyrinogen decarboxylase 
activity. GB had postulated bone-marrow expression 
of familial PCT, and AB had classic familial sub-type 
of the disease 
b n, number of assays per patient 
’ K,,, values, determined as described in the text using 
uroporphyrinogen III as substrate, were measured 
together under identical assay conditions 
d 4. coefficient of determination for the line from which 
the kinetic constants were derived 
tients GB and AB, respectively, 
0.31 PM for the non-porphyric 
(FJMc). 
as compared to 
control subject 
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Fig.2. Inhibition of the activities of uroporphyrinogen 
decarboxylases, purified to lOOOO-fold from the red cells 
of a normal control, FMc (0) and 2 familial PCT 
patients GB (0) and AB (A), by ferrous iron used as 
ferrous ammonium sulfate. V, activity in the presence of 
Fe’+; V,, control activity. Enzyme activities were 
measured by HPLC method using pentacarboxylic 
porphyrinogen I as substrate. 
Results presented in fig.2 show progressive in- 
hibition of the enzyme activities both from normal 
subject and PCT patients by increasing concentra- 
tion of ferrous ammonium sulfate. However, the 
inhibitions by iron of the abnormal enzymes were 
significantly higher as compared to the normal en- 
zyme (about 50 and 20% inhibitions, respectively, 
by 0.1 mM Fe’+). 
4. DISCUSSION 
Recent observations of a proportional relation- 
ship between catalytic activity and immunoreac- 
tivity (CRIM-negative) for red cell uropor- 
phyrinogen decarboxylase [ 13- 151 both in familial 
and sporadic forms of PCT as well as in normal 
controls imply that the observed 50% reduced en- 
zyme activity in familial PCT [3-51 represents 
diminished amounts of ‘normal’ enzyme. The data 
in this study show for the first time that the 
Michaelis constants (Km) of highly purified 
(lOOOO-fold) enzyme preparations from familial 
PCT was about 3.2-fold higher than similarly 
purified red cell enzyme from the non-porphyric 
control subject with respect to uroporphyrinogen 
III substrate (fig. 1 and table 1). These data strong- 
ly support and extend our previous observations 
with about 200-fold purified red cell uropor- 
phyrinogen decarboxylase preparations [l] that the 
inherent biochemical defect in human PCT is sub- 
normal enzyme-substrate affinity. This would sug- 
gest that the antiuroporphyrinogen decarboxylase 
antibodies used for immunoquantitation studies 
[ 13-151 did not recognize the antigenic site(s) of 
the mutant enzyme in PCT, or that the kinetic ab- 
normalities are due to point mutation in the struc- 
tural gene. 
The observations of’ in vitro inhibition of 
uroporphyrinogen decarboxylase activities by iron 
in the highly purified erythrocyte uropor- 
phyrinogen decarboxylase enzyme preparations 
(fig.2) are new, and contrast with the conflicting 
data reported elsewhere of no [ 161, insignificant 
[17] or inhibition with excess (2-4 mM) Fe2+ 
[ 18,191, or only following pre-incubation of the en- 
zyme and iron with cysteine [20]. The noteworthy 
observations are that mutation confers higher 
susceptibility to inhibition by iron of the abnormal 
enzymes as compared to the normal uropor- 
phyrinogen decarboxylase. These results support 
our previous observations [l] that the enzyme from 
PCT patients might have an intrinsically abnormal 
conformation. 
The data presented in this study, suggest that 
perturbation of hepatic decarboxylation of por- 
phyrinogens by reduced substrate affinity could be 
enhanced by the 2 independent effects of ferrous 
iron i.e. direct competitive inhibition, and oxygen- 
dependent effects on the substrate and/or enzyme 
as reported by us elsewhere [2]. The dual pre- 
requisites i.e. a metabolic lesion in heme biosyn- 
thesis and its expression by hepatic iron tie in nice- 
ly with the well known observations (i) that only a 
small proportion of patients with hemochromat- 
osis or alcoholic liver disease develop PCT, (ii) that 
in family studies less than 20% of relatives with 
demonstrated evidence of red cell uropor- 
phyrinogen decarboxylase deficiency have por- 
phyria and (iii) why, in PCT patients where reduc- 
tion of hepatic iron has led to biochemical remis- 
sion, the diminished hepatic uroporphyrinogen 
decarboxylase activity is not restored to normal 
[21,22]. 
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